New research has suggested that regularly eating yoghurt could help people avoid cancer.

The study looked at results based on 80,000 patients over the course of nine years and found that two servings of the dairy food per day could significantly reduce risk of developing disease.

Conducted by Sweden's Karolinska Institute in Stockholm, it was also noted that regularly eating other dairy products had no benefits, but yoghurt could help to fight disease.

The findings are set to be published in the American Journal of Clinical Nutrition and conclude that two portions each day can reduce the risk of cancer development by 45 per cent in women and 36 per cent in men.

"Cultured milk products, such as yogurt, contain lactic acid bacteria, which have been shown to suppress bladder cancer in rats," the report states. "Our research suggests a high intake may reduce the risk [in humans]."

The Express notes that around 10,000 people in the UK are diagnosed with bladder cancer each year.

Login and visit the HPV & Cervical Cancer Knowledge Centre

• Study highlights lack of sleep and exercise as cancer risk 18/11/08
• Doctors warned over pre-eclampsia risk in pregnant women 05/11/08
• Gender link explored in CHD research 14/10/08
• Additional testing may improve breast cancer risk assessment 29/07/08
• Heart disease linked to early stage dementia 23/07/08

• TRITACE Tablets - 24.72%
  ... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ...
  
  
• TRITACE Titration Pack - 24.36%
  ... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ...
  
  
• BETAFERON - 23.54%
  ... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ...
  
  
• LOCOID Ointment - 22.5%
  The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ...
  
  
• NAGLAZYME Solution for Infusion - 22.5%
  ... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ...
  
  
• ELAPRASE Solution for Infusion - 22.5%
  Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...